Connect with us


Key Events This Busy Week: PCE, Employment Costs, Durables And Barrage Of Earnings

Key Events This Busy Week: PCE, Employment Costs, Durables And Barrage Of Earnings

It’ a busy week with over a hundred companies reporting,…



Key Events This Busy Week: PCE, Employment Costs, Durables And Barrage Of Earnings

It' a busy week with over a hundred companies reporting, and a barrage of economic data on deck. According to DB's Jim Reid, the week is also important for European inflation with German CPI on Thursday and the French and Italian equivalent (plus PPI) on Friday with the overall Euro CPI the same day. US (Thursday) and European Q1 GDP (Friday) will also be of interest. Unlike last week, when a relentless barrage of chattering central bank uberhawks sent stocks spiraling lower, we are now in the Fed blackout period ahead of the FOMC's meeting in the first week of May, so they won't add to the hawkishness for the 9.5 days before we get the FOMC decision. Note that the BoJ meet on Thursday although nothing suggests they are going to pivot and will remain the last hawkish shoe to drop.

Back to the US where inflation-related data will be the closest watched with Friday's ECI expected to be strong. This is one of the key indicators the Fed use for labor market strength. The core PCE deflator (the Fed's preferred inflation measure) also comes out as part of the income and spending report data on Friday. The rate of growth may well tick down here so this might provide a shred of good news on inflation without changing the story too much.

It is also a crucial week for corporate earnings with 179 of the S&P 500 reporting and 134 in the Stoxx 600. Big US tech will be the highlight with Microsoft and Alphabet (tomorrow), Meta (Wednesday), and Apple and Amazon (Thursday). Some context here: the Nasdaq 100 Index has erased about $1 trillion in market value since Netflix released disappointing earnings and is closing in on oversold levels; the tech-heavy FANGMAN basket has lost $2.4 trillion in market cap from 2021 ATH as Netflix and Facebook  Meta, have lost most of their gains from past 5yrs. Remember when Facebook hit the $1tn market cap club in 2021? Now it’s worth exactly half that.

Meanwhile, consumption patterns will be in focus when we get results from Coca-Cola (today), Mondelez, Chipotle (tomorrow), Kraft Heinz (Wednesday) and McDonald's (Thursday). Meanwhile, a range of banks across the globe will give a pulse check on consumer credit. Notable reporters will include HSBC, UBS, Santander (tomorrow), Credit Suisse (Wednesday), Barclays (Thursday), finishing with BBVA and NatWest on Friday. Other notable financials reporting will include Visa (tomorrow), PayPal (Wednesday) and Mastercard (Thursday).

Other tech-related companies releasing results will include Activision Blizzard (Monday), LG, Qualcomm, Spotify (Wednesday), Samsung, Intel and Twitter (Thursday). In healthcare, another sector that benefitted from the pandemic, reporters will include Novartis (tomorrow), GlaxoSmithKline (Wednesday), Eli Lilly, Merck, Sanofi (Thursday) and AstraZeneca (Friday).

To see how the commodity rally and the focus on energy transition affected major commodity companies worldwide, markets will get earnings from Iberdrola, Vale (Wednesday), Total, Repsol (Thursday), Exxon, Orsted, Chevron and Eni (Friday). Downstream users like transport firms will report too, including General Motors (tomorrow), Boeing, Mercedes-Benz and Ford (Wednesday). Other notable corporates releasing results will include Texas Instruments, General Electric, UPS and Caterpillar.

The rest of the day by day calendar of events is shown below.

Day-by-day calendar of events

Monday April 25

  • Data: US April Dallas Fed Manufacturing activity, March Chicago Fed national activity index, Japan March services PPI, Germany April
  • IFO business climate, Eurozone February construction output
  • Earnings: Coca-Cola, Activision Blizzard, Vivendi

Tuesday April 26

  • Data: US April Conference Board consumer confidence, Richmond Fed manufacturing index, March durable goods orders, new home sales, February FHFA house price index, Japan March jobless rate, UK March public finances
  • Central banks: ECB's Villeroy speaks
  • Earnings: Microsoft, Alphabet, Atlas Copco, Visa, PepsiCo, Novartis, UPS, Texas Instruments, Raytheon Technologies, Ganfeng Lithium, HSBC, General Electric, Mondelez, 3M, UBS, General Motors, Capital One, Warner Bros Discovery, Santander, ADM, Valero, Chipotle, MSCI

Wednesday April 27

  • Data: US March wholesale inventories, pending home sales, China March industrial profits, Germany May GfK consumer confidence, France April consumer confidence
  • Earnings: LG, Meta, Vale, T-Mobile, Qualcomm, Amgen, Yara, Boeing, PayPal, Canadian Pacific, GlaxoSmithKline, Mercedes-Benz, Iberdrola, Ford, Kraft Heinz, Hess, Lloyds, Spotify, UniCredit, Credit Suisse, Hertz

Thursday April 28

  • Data: US Q1 GDP, personal consumption, core PCE, initial jobless claims, April Kansas City Fed manufacturing activity, Japan March retail sales, industrial production, housing starts, Germany April CPI, Italy April consumer, manufacturing confidence, economic sentiment, March hourly wages, February industrial sales, Eurozone April economic confidence
  • Central banks: BoJ decision, ECB's Economic Bulletin, ECB's Wunsch speaks
  • Earnings: Samsung, Apple, Amazon, Mastercard, Eli Lilly, Thermo Fisher Scientific, Merck, Comcast, Intel, McDonald's, Swedbank, Linde, Sanofi, Caterpillar, TotalEnergies, Gilead Sciences, Twitter, Nordic Semiconductor, PG&E, Southwest Airlines, Nokia, Barclays, Repsol, Carlyle, Zendesk, Roku

Friday April 29

  • Data: US Q1 employment cost index, March personal income and spending, PCE deflator, April MNI Chicago PMI, France April CPI, March consumer spending, PPI, Q1 GDP, Italy Q1 GDP, April CPI, March PPI, Germany Q1 GDP, March import price index, Eurozone Q1 GDP, April CPI, March M3, Canada February GDP
  • Earnings: Bank of China, Exxon Mobil, Orsted, Chevron, AbbVie, Bristol-Myers Squibb, AstraZeneca, Honeywell, DBS, Colgate-Palmolive, Eni, Neste Oyj, BBVA, NIO, CaixaBank, NatWest

* * *

Finally, looking at just the US, Goldman writes that the key economic data releases this week are the durable goods report on Tuesday, the Q1 GDP advance release on Thursday, and the employment cost index and core PCE reports on Friday. There are no speaking engagements from Fed officials this week, reflecting the FOMC blackout period.

Monday, April 25

  • 10:30 AM Dallas Fed manufacturing index, April (consensus 4.5, last 8.7)

Tuesday, April 26

  • 08:30 AM Durable goods orders, March preliminary (GS +0.7%, consensus +1.0%, last -2.1%); Durable goods orders ex-transportation, March preliminary (GS +0.7%, consensus +0.6%, last -0.6%); Core capital goods orders, March preliminary (GS +0.7%, consensus +0.4%, last -0.2%); Core capital goods shipments, March preliminary (GS +0.7%, consensus +0.5%, last +0.3%): We estimate that durable goods orders increased 0.7% in the preliminary March report, following a 2.1% decline in February.
  • 09:00 AM FHFA house price index, February (consensus +1.5%, last +1.6%)
  • 09:00 AM S&P/Case-Shiller 20-city home price index, February (GS +1.6%, consensus +1.50%, last +1.79%); We estimate that the S&P/Case-Shiller 20-city home price index rose by 1.6% in February, following a 1.79% (19.1% yoy) increase in January.
  • 10:00 AM Conference Board consumer confidence, April (GS 107.2, consensus 108.5, last 107.2); We estimate that the Conference Board consumer confidence index was flat at 107.2 in April, reflecting weaker signals from other confidence measures.
  • 10:00 AM New home sales, March (GS -1.0%, consensus +1.3%, last -2.0%): We estimate that new home sales declined 1.0% in March, following a 2.0% decline in February.
  • 10:00 AM Richmond Fed manufacturing index, April (consensus 8, last 13)

Wednesday, April 27

  • 08:30 AM Advance goods trade balance, March (GS -$110.0bn, consensus -$105.0bn, last -$106.3bn); We estimate that the goods trade deficit increased by $3.7bn to $110.0bn in March compared to the final February report, reflecting an increase in imports.
  • 08:30 AM Wholesale inventories, March preliminary (consensus +1.5%, last +2.5%): Retail inventories, March (consensus +1.6%, last +1.1%)
  • 10:00 AM Pending home sales, March (GS -2.0%, consensus -1.0%, last -4.1%): We estimate that pending home sales decreased by 2.0% in March, following a 4.1% decrease in February.

Thursday, April 28

  • 08:30 AM Initial jobless claims, week ended April 23 (GS 185k, consensus 180k, last 184k); Continuing jobless claims, week ended April 16 (consensus 1,393k, last 1,417k): We estimate that initial jobless claims edged up to 185k in the week ended April 23.
  • 08:30 AM GDP, Q1 advance (GS +1.5%, consensus, +1.0%, last +6.9%); Personal consumption, Q1 advance (GS +3.6%, consensus +3.4%, last +2.5%): We estimate that GDP growth slowed to +1½% annualized in the advance reading for Q1, following a 6.9% annualized increase in Q4. Our forecast reflects firming consumption growth (to +3.6%) and strong growth in business structures and equipment investment, offset by a drag from net exports (-2.1pp). We also expect a negative contribution from slower inventory growth (-0.8pp), following a strong positive contribution in Q4 (+5.1pp).
  • 11:00 AM Kansas City Fed manufacturing index, April (consensus +35, last +37)

Friday, April 29

  • 08:30 AM Employment cost index, Q1 (GS +1.3%, consensus +1.1%, prior +1.0%): We estimate that the employment cost index rose 1.3% in Q1 (qoq sa), which would boost the year-on-year rate by five tenths to +4.5%. Our forecast reflects larger-than-normal annual raises due to labor shortages and the elevated quits rate. Relatedly, the share of workers with unchanged wages fell to a 15-year low in the quarter (11%, yoy basis, Atlanta Fed wage tracker). Incentive-paid industries also weighed on the Q4 ECI reading, whereas we expect a flat or positive contribution in Q1.
  • 08:30 AM Personal income, March (GS +0.5%, consensus +0.4%, last +0.5%); Personal spending, March (GS +0.7%, consensus +0.6%, last +0.2%); PCE price index, March (GS +0.83%, consensus +0.9%, last +0.58%); PCE price index (yoy), March (GS +6.63%, consensus +6.7%, last +6.35%); Core PCE price index, March (GS +0.25%, consensus +0.3%, last +0.35%); Core PCE price index (yoy), March (GS +5.22%, consensus +5.3%, last +5.40%): Based on details in the PPI, CPI, and import price reports, we forecast that the core PCE price index rose by 0.25% month-over-month in March, corresponding to a 5.22% increase from a year earlier. Additionally, we expect that the headline PCE price index increased by 0.83% in March, corresponding to a 6.63% increase from a year earlier. We expect that personal income increased by 0.5% and personal spending increased by 0.7% in March.
  • 09:45 AM Chicago PMI, April (GS 62.9, consensus 62.0, last 62.9): We estimate that the Chicago PMI was unchanged in April at 62.9.
  • 10:00 AM University of Michigan consumer sentiment, April final (GS 65.0, consensus 65.7, last 65.7): We expect the University of Michigan consumer sentiment index decreased by 0.7pt to 65.0 in the final April reading.

Source: DB, BofA, Goldman

Tyler Durden Mon, 04/25/2022 - 09:30

Read More

Continue Reading


Who Can You Trust?

Who Can You Trust?

Authored by James Howard Kunstler via,

“I’m sick and tired of hearing Democrats whining about Joe Biden’s…



Who Can You Trust?

Authored by James Howard Kunstler via,

“I’m sick and tired of hearing Democrats whining about Joe Biden’s age. The man knows how to govern. Just shut up and vote to save Democracy.”

- Rob Reiner, Hollywood savant

Perhaps you’re aware that the World Health Organization (WHO) is cooking up a plan to impose its will over all the sovereign nations on this planet in the event of future pandemics.

That means, for instance, that the WHO would issue orders to the USA about lockdowns, vaccines, and vaccine passports and we US citizens supposedly would be compelled to follow them.

Why the “Joe Biden” regime would go along with this globalist fuckery is one of the abiding mysteries of our time - except that they go along with everything else that the cabal of Geneva cooks up, such as attacks on farmers, and on oil production, and on relations between men and women, and on personal privacy, and on economic liberty throughout Western Civ, as if they’re working overtime to kill it off. And all of us with it.

I think they are working overtime at that because the sore-beset citizens of Western Civ are onto their game, and getting restless about it. So, the Geneva cabal is in a race against time before the center pole of their circus tent collapses and the nations of the world are compelled to follow the zeitgeist in the direction of de-centralizing, foiling all their grand plans.

The “Joe Biden” regime is pretending to ignore the reality that this WHO deal is actually a treaty that would require ratification by a two-thirds vote in the senate, an unlikely outcome. In any case, handing over authority to the WHO — in effect, to its chief Tedros Adhanom Ghebreyesus — to push around American citizens like a giant herd of cattle would be patently unlawful.

That center pole of the circus tent is the wobbling global economy. It’s barely holding up the canvas over the three rings of the circus. In the center ring, the death-defying spectacle of the Biden Family crime case is playing out before a huge audience (us). This week, a gun went off at the FBI and smoke is curling out of the barrel. FBI Director Christopher Wray was forced to verify that he’s been sitting on an incriminating document for three years from a “trusted” confidential human source, i.e., an informant, stating that the Biden Family received a $5-million bribe from a foreign entity when “JB” was vice-president.

That’s only one bribe of many others, of course, as documented in the Hunter Biden laptop, and it must be obvious it represents treasonous behavior that will demand resignation or impeachment. As this spools out in the weeks and months ahead, do you think Americans will be in the mood to accept further insults such as “Joe Biden” surrendering our national sovereignty to the WHO?

Anyway, you must ask yourself: why on earth should I trust the WHO about anything? Did they not participate in laying a trip on the world with Covid-19? How did those lockdowns work out? Do you think they destroyed enough businesses and ruined enough households? How’s the vaccination program doing? Effective? Safe? Yeah, maybe not so much. Maybe killing a lot of people, wrecking immune systems, sterilizing reproductive organs, causing gross disabilities, shattering lives.

Of course, in over three years neither the WHO nor the US medical authorities showed the slightest interest in helping to figure out how the Covid-19 virus was made in a lab, and exactly how it got loose in the world. Lately, Dr. Ghebreyesus has warned the world about much worse future pandemics supposedly coming down at us. Oh? Really? What does he know that we don’t? That possibly new efforts to concoct chimeric diseases are ongoing in labs around the world? (You know that dozens of such labs were discovered in Ukraine as the war got underway there in 2022.) What’s Dr. Ghebreyesus doing to stop that?

If US orgs and citizens are involved in this “research,” why doesn’t the WHO alert our government leaders so they can stop it? (Would they? I’m not so sure.) And, who is behind it this time? The Eco-Health Alliance again, like with Covid-19? By the way, that outfit got another whopping grant last fall from the NIH to “study” bat viruses — right after the NIH terminated a previous grant on account of The Eco-Health Alliance failing to turn over notebooks and other records.

No, you cannot trust the WHO about anything. The “trust horizon” (a concept introduced by the great Nicole Foss, late of The Automatic Earth dot com) is shrinking. You can no longer trust any distant authorities. You also cannot trust the US federal government (especially the executive branch behind “Joe Biden”). And notice: the trust horizon is shrinking just as the world is de-centralizing. This, you see, is the main contradiction behind all the Globalists’ twisted ambitions to control everything, including you. They are working against the current tide of human history which is pushing everything toward down-scaling, re-localization, and re-assertion of the sovereign individual person.

That trend will become increasingly evident as things organized at the giant scale start to implode — giant retail chains, medical behemoths, hedge funds, big banks, you name it. The world no longer has the mojo for globalism. There’s reason to wonder these days whether the USA has the mojo to remain a unified national polity of states. Our federal government is not only financially bankrupt beyond any coherent reckoning, it is also morally bankrupt, and it has decided to make war against its own people. None of this is satisfactory and none of this is working. It’s time to figure out who and what you can trust and act accordingly.

Tyler Durden Sun, 06/04/2023 - 09:20

Read More

Continue Reading


Removing antimicrobial resistance from the WHO’s ‘pandemic treaty’ will leave humanity extremely vulnerable to future pandemics

Drug-resistant microbes are a serious threat for future pandemics, but the new draft of the WHO’s international pandemic agreement may not include provisions…




Antimicrobial resistance is now a leading cause of death worldwide due to drug-resistant infections, including drug-resistant strains of tuberculosis, pneumonia and Staph infections like the methicillin-resistant Staphylococcus aureus shown here. (NIAID, cropped from original), CC BY

In late May, the latest version of the draft Pandemic Instrument, also referred to as the “pandemic treaty,” was shared with Member States at the World Health Assembly. The text was made available online via Health Policy Watch and it quickly became apparent that all mentions of addressing antimicrobial resistance in the Pandemic Instrument were at risk of removal.

Work on the Pandemic Instrument began in December 2021 after the World Health Assembly agreed to a global process to draft and negotiate an international instrument — under the Constitution of the World Health Organization (WHO) — to protect nations and communities from future pandemic emergencies.

Read more: Drug-resistant superbugs: A global threat intensified by the fight against coronavirus

Since the beginning of negotiations on the Pandemic Instrument, there have been calls from civil society and leading experts, including the Global Leaders Group on Antimicrobial Resistance, to include the so-called “silent” pandemic of antimicrobial resistance in the instrument.

Just three years after the onset of a global pandemic, it is understandable why Member States negotiating the Pandemic Instrument have focused on preventing pandemics that resemble COVID-19. But not all pandemics in the past have been caused by viruses and not all pandemics in the future will be caused by viruses. Devastating past pandemics of bacterial diseases have included plague and cholera. The next pandemic could be caused by bacteria or other microbes.

Antimicrobial resistance

Yellow particles on purple spikes
Microscopic view of Yersinia pestis, the bacteria that cause bubonic plague, on a flea. Plague is an example of previous devastating pandemics of bacterial disease. (NIAID), CC BY

Antimicrobial resistance (AMR) is the process by which infections caused by microbes become resistant to the medicines developed to treat them. Microbes include bacteria, fungi, viruses and parasites. Bacterial infections alone cause one in eight deaths globally.

AMR is fueling the rise of drug-resistant infections, including drug-resistant tuberculosis, drug-resistant pneumonia and drug-resistant Staph infections such as methicillin-resistant Staphylococcus aureus (MRSA). These infections are killing and debilitating millions of people annually, and AMR is now a leading cause of death worldwide.

Without knowing what the next pandemic will be, the “pandemic treaty” must plan, prepare and develop effective tools to respond to a wider range of pandemic threats, not solely viruses.

Even if the world faces another viral pandemic, secondary bacterial infections will be a serious issue. During the COVID-19 pandemic for instance, large percentages of those hospitalized with COVID-19 required treatment for secondary bacterial infections.

New research from Northwestern University suggests that many of the deaths among hospitalized COVID-19 patients were associated with pneumonia — a secondary bacterial infection that must be treated with antibiotics.

An illustrative diagram that shows the difference between a drug resistant bacteria and a non-resistant bacteria.
Antimicrobial resistance means infections that were once treatable are much more difficult to treat. (NIAID), CC BY

Treating these bacterial infections requires effective antibiotics, and with AMR increasing, effective antibiotics are becoming a scarce resource. Essentially, safeguarding the remaining effective antibiotics we have is critical to responding to any pandemic.

That’s why the potential removal of measures that would help mitigate AMR and better safeguard antimicrobial effectiveness is so concerning. Sections of the text which may be removed include measures to prevent infections (caused by bacteria, viruses and other microbes), such as:

  • better access to safe water, sanitation and hygiene;
  • higher standards of infection prevention and control;
  • integrated surveillance of infectious disease threats from human, animals and the environment; and
  • strengthening antimicrobial stewardship efforts to optimize how antimicrobial drugs are used and prevent the development of AMR.

The exclusion of these measures would hinder efforts to protect people from future pandemics, and appears to be part of a broader shift to water-down the language in the Pandemic Instrument, making it easier for countries to opt-out of taking recommended actions to prevent future pandemics.

Making the ‘pandemic treaty’ more robust

Measures to address AMR could be easily included and addressed in the “pandemic treaty.”

In September 2022, I was part of a group of civil society and research organizations that specialize in mitigating AMR who were invited the WHO’s Intergovernmental Negotiating Body (INB) to provide an analysis on how AMR should be addressed, within the then-draft text.

They outlined that including bacterial pathogens in the definition of “pandemics” was critical. They also identified specific provisions that should be tweaked to track and address both viral and bacterial threats. These included AMR and recommended harmonizing national AMR stewardship rules.

In March 2023, I joined other leading academic researchers and experts from various fields in publishing a special edition of the Journal of Medicine, Law and Ethics, outlining why the Pandemic Instrument must address AMR.

The researchers of this special issue argued that the Pandemic Instrument was overly focused on viral threats and ignored AMR and bacterial threats, including the need to manage antibiotics as a common-pool resource and revitalize research and development of novel antimicrobial drugs.

Next steps

While earlier drafts of the Pandemic Instrument drew on guidance from AMR policy researchers and civil society organizations, after the first round of closed-door negotiations by Member States, all of these insertions, are now at risk for removal.

The Pandemic Instrument is the best option to mitigate AMR and safeguard lifesaving antimicrobials to treat secondary infections in pandemics. AMR exceeds the capacity of any single country or sector to solve. Global political action is needed to ensure the international community works together to collectively mitigate AMR and support the conservation, development and equitable distribution of safe and effective antimicrobials.

By missing this opportunity to address AMR and safeguard antimicrobials in the Pandemic Instrument, we severely undermine the broader goals of the instrument: to protect nations and communities from future pandemic emergencies.

It is important going forward that Member States recognize the core infrastructural role that antimicrobials play in pandemic response and strengthen, rather than weaken, measures meant to safeguard antimicrobials.

Antimicrobials are an essential resource for responding to pandemic emergencies that must be protected. If governments are serious about pandemic preparedness, they must support bold measures to conserve the effectiveness of antimicrobials within the Pandemic Instrument.

Susan Rogers Van Katwyk is a member of the WHO Collaborating Centre on Global Governance of Antimicrobial Resistance at York University. She receives funding from the Wellcome Trust and the Social Sciences and Humanities Research Council of Canada.

Read More

Continue Reading

Spread & Containment

Repeated COVID-19 Vaccination Weakens Immune System: Study

Repeated COVID-19 Vaccination Weakens Immune System: Study

Authored by Zachary Stieber via The Epoch Times (emphasis ours),

Repeated COVID-19…



Repeated COVID-19 Vaccination Weakens Immune System: Study

Authored by Zachary Stieber via The Epoch Times (emphasis ours),

Repeated COVID-19 vaccination weakens the immune system, potentially making people susceptible to life-threatening conditions such as cancer, according to a new study.

A man is given a COVID-19 vaccine in Chelsea, Mass., on Feb. 16, 2021. (Joseph Prezioso/AFP via Getty Images)

Multiple doses of the Pfizer or Moderna COVID-19 vaccines lead to higher levels of antibodies called IgG4, which can provide a protective effect. But a growing body of evidence indicates that the “abnormally high levels” of the immunoglobulin subclass actually make the immune system more susceptible to the COVID-19 spike protein in the vaccines, researchers said in the paper.

They pointed to experiments performed on mice that found multiple boosters on top of the initial COVID-19 vaccination “significantly decreased” protection against both the Delta and Omicron virus variants and testing that found a spike in IgG4 levels after repeat Pfizer vaccination, suggesting immune exhaustion.

Studies have detected higher levels of IgG4 in people who died with COVID-19 when compared to those who recovered and linked the levels with another known determinant of COVID-19-related mortality, the researchers also noted.

A review of the literature also showed that vaccines against HIV, malaria, and pertussis also induce the production of IgG4.

“In sum, COVID-19 epidemiological studies cited in our work plus the failure of HIV, Malaria, and Pertussis vaccines constitute irrefutable evidence demonstrating that an increase in IgG4 levels impairs immune responses,” Alberto Rubio Casillas, a researcher with the biology laboratory at the University of Guadalajara in Mexico and one of the authors of the new paper, told The Epoch Times via email.

The paper was published by the journal Vaccines in May.

Pfizer and Moderna officials didn’t respond to requests for comment.

Both companies utilize messenger RNA (mRNA) technology in their vaccines.

Dr. Robert Malone, who helped invent the technology, said the paper illustrates why he’s been warning about the negative effects of repeated vaccination.

“I warned that more jabs can result in what’s called high zone tolerance, of which the switch to IgG4 is one of the mechanisms. And now we have data that clearly demonstrate that’s occurring in the case of this as well as some other vaccines,” Malone, who wasn’t involved with the study, told The Epoch Times.

So it’s basically validating that this rush to administer and re-administer without having solid data to back those decisions was highly counterproductive and appears to have resulted in a cohort of people that are actually more susceptible to the disease.”

Possible Problems

The weakened immune systems brought about by repeated vaccination could lead to serious problems, including cancer, the researchers said.

Read more here...

Tyler Durden Sat, 06/03/2023 - 22:30

Read More

Continue Reading